Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
CPRX's Cash-to-Debt is ranked higher than
97% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. CPRX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CPRX' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
CPRX's Interest Coverage is ranked higher than
97% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. CPRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CPRX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 36.36
Beneish M-Score: -3.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -41.21
CPRX's ROE % is ranked lower than
84% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. CPRX: -41.21 )
Ranked among companies with meaningful ROE % only.
CPRX' s ROE % Range Over the Past 10 Years
Min: -137.75  Med: -57.88 Max: -22.89
Current: -41.21
-137.75
-22.89
ROA % -38.83
CPRX's ROA % is ranked lower than
86% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. CPRX: -38.83 )
Ranked among companies with meaningful ROA % only.
CPRX' s ROA % Range Over the Past 10 Years
Min: -105.81  Med: -51.22 Max: -22.19
Current: -38.83
-105.81
-22.19
ROC (Joel Greenblatt) % -2036.08
CPRX's ROC (Joel Greenblatt) % is ranked lower than
92% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. CPRX: -2036.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CPRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -20616.95  Med: -3301.25 Max: -485.88
Current: -2036.08
-20616.95
-485.88
3-Year EBITDA Growth Rate 0.90
CPRX's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. CPRX: 0.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CPRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.7  Med: 1.7 Max: 51.2
Current: 0.9
-30.7
51.2
3-Year EPS without NRI Growth Rate -6.60
CPRX's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. CPRX: -6.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CPRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: 7.1 Max: 48.5
Current: -6.6
-33.7
48.5
GuruFocus has detected 2 Warning Signs with Catalyst Pharmaceuticals Inc $CPRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CPRX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CPRX Guru Trades in Q2 2016

Steven Cohen 2,366,964 sh (+4.57%)
Jim Simons Sold Out
» More
Q3 2016

CPRX Guru Trades in Q3 2016

Jim Simons 15,000 sh (New)
Steven Cohen 2,366,964 sh (unchged)
» More
Q4 2016

CPRX Guru Trades in Q4 2016

Jim Simons Sold Out
Steven Cohen 2,272,816 sh (-3.98%)
» More
Q1 2017

CPRX Guru Trades in Q1 2017

Jim Simons 382,400 sh (New)
Steven Cohen 877,266 sh (-61.40%)
» More
» Details

Insider Trades

Latest Guru Trades with CPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:STDY, NAS:DRRX, OTCPK:ELTP, OTCPK:CURR, NAS:NEOS, OTCPK:OGRMF, OTCPK:CMMDF, OTCPK:ZOMHF, NAS:SMMT, NAS:MSLI, NAS:ZYNE, OTCPK:CPHRF, OTCPK:EMMBF, NAS:ADMP, OTCPK:ACNNF, NAS:CPIX, NAS:COLL, OTCPK:OWCP, NAS:ARLZ, NAS:AGRX » details
Traded in other countries:CN2.Germany,
Headquarter Location:USA
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for people with rare debilitating diseases.

Catalyst Pharmaceuticals Inc was incorporated in Delaware in July 2006. The Company is a biopharmaceutical company. The Company is engaged in developing and commercializing therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette syndrome. Catalyst's candidate, Firdapse for the treatment of LEMS, recently completed testing in a global, multi-center, pivotal Phase 3 trial resulting in positive top-line data. Firdapse for the treatment of LEMS has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and orphan drug designation for CMS. Firdapse is the first and only European approved drug for symptomatic treatment in adults with LEMS. The Company is also enagaged in developing CPP-115 to treat infantile spasms, epilepsy and other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette syndrome. It has three pharmaceutical products in development namely Firdapse(tm), CPP-115 and CPP-109. The Company also competes against biotechnology companies, universities, government agencies, and other research institutions in the development of substance abuse treatments, technologies and processes. The pharmaceutical industry is intensely competitive, and any product candidate developed or licensed by the Company would likely compete with existing drugs and therapies. In the United States, drugs are subject to rigorous regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations, as well as other federal and state statutes.

Top Ranked Articles about Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Receives 2017 Beacon Council Award for Contributions in Life Sciences & Healthcare
Catalyst Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update
Catalyst Pharmaceuticals Announces Poster Presentation of MuSK-MG clinical data at the 13th International Conference on Myasthenia Gravis and Related Disorders
Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thursday, May 11th, 2017
Catalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored Trial of Firdapse® in treating MuSK Antibody Positive Myasthenia Gravis

Catalyst intends to proceed to U.S. multi-center pivotal trialExpects additional data to be presented at upcoming medical congresses in 2017 CORAL GABLES, Fla., March 15, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare neuromuscular and neurological diseases, today announced positive top-line results from the investigator-sponsored trial evaluating Firdapse® (Amifampridine Phosphate) as a treatment for myasthenia gravis patients with anti-MuSK antibodies (MuSK-MG). MuSK-MG, is an ultra-rare sub-population of myasthenia Gravis (MG) patients which is a debilitating neuromuscular disease, and there are currently no FDA approved therapies for this specific form of MG.  Both of the co-primary efficacy endpoints of change from baseline (CFB) in total Quantitative Myasthenia Gravis (QMG) score (p=0.0003) and CFB in total Myasthenia Gravis Activities of Daily Living (MG-ADL) score (p=0.0006) were statistically and clinically significant in this seven patient trial.  Several secondary efficacy measures also achieved statistical significance.  Amifampridine phosphate was well tolerated in this population of patients. The study was conducted by a team of researchers led by Renato Mantegazza, MD, Director, Department of Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico Carlo Besta in Milan, Italy, a major referral center for MuSK-MG patients.  The study was designed as a randomized (1:1), double-blind, placebo-controlled, crossover, outpatient study to evaluate the safety, tolerability and potential efficacy of amifampridine phosphate in patients diagnosed with MuSK-MG.  Catalyst provided funding, study drug, and placebo for this trial. Dr. Mantegazza, the principal investigator of this trial, stated, “Our prospective study evaluating amifampridine phosphate for the symptomatic relief of antibody positive MuSK-MG was statistically significant in demonstrating that it can be an important treatment option.  Not only are the results statistically significant, but more importantly, there was a large clinical benefit to the patients.  Current treatments for MuSK-MG patients are often inadequate and these patients often face a lifetime of severe complications, including difficulty walking, talking, swallowing, and breathing normally, and in some cases their disease may be life-threatening and require hospitalization and intensive care.  Amifampridine phosphate may offer us an effective treatment option.  I look forward to the day when I can use this drug in routine clinical practice of treating MuSK-MG patients.” Dr. Silvia Bonanno, one of the investigators from the Istituto Neurologico Carlo Besta, is planning to present these results at the 13th International Conference on Myasthenia Gravis and Related Disorders in May, 2017 in New York City, provided her abstract is accepted as a Hot Topic Short Talk.  This conference is organized by the Myasthenia Gravis Foundation of America and the New York Academy of Sciences. “These data announced today should allow us to accelerate our MuSK-MG program over the coming months, as we expect to consult with our external experts and regulatory agencies on a pivotal clinical development plan,” said Patrick J. McEnany, Catalyst’s Chief Executive Officer. “I would like to thank Dr. Mantegazza, his associates at Carlo Besta Neurological Institute, and the patients that participated in this important clinical trial.” "While several effective treatment options exist for the anti-acetylcholine receptor form of myasthenia gravis (AcHR-MG), MuSK-MG has been particularly refractory to current MG treatment options and represents an unmet medical need in the MG community of patients," stated Gary Ingenito MD, Ph.D., Catalyst's Chief Medical Officer.  Dr. Ingenito continued: "If the significant clinical effect observed in this trial is reproduced in a multicenter trial, amifampridine phosphate would, upon approval, likely become the first line standard of care for MuSK-MG.  Based on these results we intend to discuss with FDA conducting a registration trial in the United States evaluating amifampridine phosphate for the symptomatic treatment of patients with MuSK-MG." About the Clinical Trial The MuSK-MG “proof-of-concept” trial was a randomized, double blind, placebo-controlled, single site, outpatient, investigator-sponsored, clinical trial to evaluate the safety and efficacy of amifampridine phosphate in myasthenia gravis patients with a positive serological test for the anti-MuSK antibodies (MuSK-MG).  Catalyst provided the investigational drug, placebo, and funding for this clinical trial. Patients were enrolled into the trial and were titrated to an effective dose of amifampridine phosphate for a period of at least 4 weeks in a "run-in" phase of the trial.  Following achievement of a dosage that effectively managed the patient's symptoms, the patients were randomized 1:1 into one of two crossover treatment groups.  There were three treatment periods in this crossover design, referred to as a "switch-back" crossover design, that enables both the determination of the effect of the treatment as well as the correction of any "subjective carryover" from earlier treatment periods into later treatment periods.  Carryover in crossover designs is a common concern of regulatory agencies, and this design effectively corrects for and eliminates the effects of carryover from the efficacy assessments.  Each treatment period lasted 1 week for a total of treatment duration of 3 weeks alternating with either amifampridine phosphate or placebo.  The co-primary efficacy endpoints of change from base (CFB) in total Quantitative Myasthenia Gravis (QMG) score and CFB in total Myasthenia Gravis Activities of Daily Living (MG-ADL) score at the 7th day of each period were assessed using a mixed carryover effects statistical model of Kunert and Stufken.  Secondary endpoints consisted of, in order, CFB in Myasthenia Gravis Composite (MGC) Score, CFB in Neurological Institute Carlo Besta-Myasthenia Gravis (NICB-MG) score, proportion of patients with a 2, or larger, point reduction in MG-ADL, proportion of patients with a 3, or larger, reduction in MGC, CFB in Myasthenia Gravis Quality of Life, 15 domain, (MG-QoL 15) score, and CFB in Fatigue Severity scale (FSS).  Catalyst's funding of this study included the use of a CRO, and this study was run as a well-controlled trial suitable for regulatory submission. About MuSK Myasthenia Gravis About 15% of MG patients test negative for the acetylcholine receptor antibody. These patients have seronegative (SN) MG. Approximately 40-50% of these patients with SNMG (equating to an estimate of approximately 4,500 patients in the United States) test positive for the anti-MuSK antibody. MuSK is a protein that is required for the maintenance of the neuromuscular junction and patients with the anti-MuSK antibody are identified as having MuSK-MG. MuSK-MG is a clinically distinguishable, more severe form of MG. The disease is characterized by a predominance in females, a prevalent involvement of cranial and bulbar muscles, high incidence of respiratory crises and a resistance to treatment. Although many patients with MuSK MG are presently treated with anticholinesterase inhibitors or immunosuppressants, such patients do not generally respond adequately to these treatments. About Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK myasthenia gravis and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS. Catalyst is also developing CPP-115 to treat refractory infantile spasms and possibly refractory Tourette's Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission.  In addition, Catalyst is developing a generic version of Sabril® (vigabatrin). Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including whether the receipt of breakthrough therapy designation for Firdapse will expedite the development and review of Firdapse by the FDA or the likelihood that the product will be found to be safe and effective, the timing of Catalyst's second trial evaluating Firdapse for the treatment of LEMS and whether the trial will be successful, whether Catalyst's assumptions in its updated business plan will be accurate and the impact of unanticipated events or delays in projected activities on Catalyst's cash requirements and on Catalyst's ability to get to an accepted NDA submission for Firdapse without the need for additional funding, what clinical trials and studies will be required before Catalyst can resubmit an NDA for Firdapse for the treatment of CMS and whether any such required clinical trials and studies will be successful, whether any NDA for Firdapse resubmitted to the FDA will ever be accepted for filing,  the timing of any such NDA filing or acceptance, whether, if an NDA for Firdapse is accepted for filing, such NDA will be given a priority review by the FDA, whether any future trial evaluating Firdapse for the treatment of MuSK-MG will be successful and whether Catalyst can obtain the funding required to conduct such trial, whether Firdapse will ever be approved for commercialization, whether Catalyst will be the first company to receive approval for amifampridine (3,4-DAP), giving it 5-year marketing exclusivity for its product, whether CPP-115 will be determined to be safe for humans, what additional testing will be required before CPP-115 is "Phase 2 ready", whether CPP-115 will be determined to be effective for the treatment of refractory infantile spasms or possibly Tourette's Disorder, or for any other indications, whether Catalyst can successfully design and complete a bioequivalence study of its version of vigabatrin compared to Sabril that is acceptable to the FDA, whether any such bioequivalence study the design of which is acceptable to the FDA will be successful, whether any ANDA that Catalyst submits for a generic version of Sabril will be accepted for filing, whether any ANDA for Sabril accepted for filing by the FDA will be approved (and the timing of any such approval), whether any of Catalyst's product candidates will ever be approved for commercialization or successfully commercialized, and those other factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2015 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
[email protected]

Media Contacts
David Schull
Russo Partners
(212) 845-4271
[email protected]

Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 529-2522
[email protected]

Read more...
Catalyst Pharmaceuticals to Present at the 29th Annual ROTH Conference

CORAL GABLES, Fla., March 10, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the 29th Annual ROTH Conference in California. Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Monday, March 13th at 9:30 am PT / 12:30 pm ET.  The Company’s presentation materials will be available on the “Investors” section of the Company’s website, www.catalystpharma.com following the presentation.
About Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS. Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission.  In addition, Catalyst is developing a generic version of Sabril® (vigabatrin). Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2015 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
[email protected]

Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 529-2522
[email protected]

Media Contacts
David Schull
Russo Partners
(212) 845-4271
[email protected]

Read more...
Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference Call and Webcast on Thursday, March 16th, 2017

CORAL GABLES, Fla., March 09, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release Fourth Quarter and Year-End 2016 financial results after market close on Wednesday, March 15, 2017. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Thursday, March 16th, 2017 to discuss the financial results and to provide a corporate update.
Investors who wish to participate in the conference call may do so by dialing (877) 407-8912 for domestic and Canadian callers or (201) 689-8059 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the company's website at www.catalystpharma.com and clicking on the webcast link on the Investors home page. A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com. About Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS. Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission.  In addition, Catalyst is developing a generic version of Sabril® (vigabatrin). Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2015 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
[email protected]

Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 529-2522
[email protected]

Media Contacts
David Schull
Russo Partners
(212) 845-4271
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 5.12
CPRX's PB Ratio is ranked lower than
64% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. CPRX: 5.12 )
Ranked among companies with meaningful PB Ratio only.
CPRX' s PB Ratio Range Over the Past 10 Years
Min: 2.35  Med: 7.34 Max: 29.61
Current: 5.12
2.35
29.61
EV-to-EBIT -8.22
CPRX's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. CPRX: -8.22 )
Ranked among companies with meaningful EV-to-EBIT only.
CPRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -23.6  Med: -5.7 Max: -1.5
Current: -8.22
-23.6
-1.5
EV-to-EBITDA -8.22
CPRX's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. CPRX: -8.22 )
Ranked among companies with meaningful EV-to-EBITDA only.
CPRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.8  Med: -5.8 Max: -1.5
Current: -8.22
-23.8
-1.5
Current Ratio 19.65
CPRX's Current Ratio is ranked higher than
97% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. CPRX: 19.65 )
Ranked among companies with meaningful Current Ratio only.
CPRX' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 14.11 Max: 54.56
Current: 19.65
0.75
54.56
Quick Ratio 19.65
CPRX's Quick Ratio is ranked higher than
97% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. CPRX: 19.65 )
Ranked among companies with meaningful Quick Ratio only.
CPRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 14.11 Max: 54.56
Current: 19.65
0.75
54.56

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.60
CPRX's 3-Year Average Share Buyback Ratio is ranked lower than
85% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. CPRX: -13.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CPRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -74.4  Med: -31.3 Max: -12.9
Current: -13.6
-74.4
-12.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.20
CPRX's Price-to-Net-Cash is ranked higher than
81% of the 206 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.25 vs. CPRX: 5.20 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CPRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.38  Med: 3.54 Max: 18.63
Current: 5.2
1.38
18.63
Price-to-Net-Current-Asset-Value 5.07
CPRX's Price-to-Net-Current-Asset-Value is ranked higher than
75% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. CPRX: 5.07 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CPRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.26  Med: 3.3 Max: 10.09
Current: 5.07
1.26
10.09
Price-to-Tangible-Book 5.07
CPRX's Price-to-Tangible-Book is ranked lower than
54% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. CPRX: 5.07 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CPRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.25  Med: 3.3 Max: 10.09
Current: 5.07
1.25
10.09
Earnings Yield (Greenblatt) % -12.19
CPRX's Earnings Yield (Greenblatt) % is ranked lower than
88% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. CPRX: -12.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CPRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -100000.2  Med: 0 Max: 2924.23
Current: -12.19
-100000.2
2924.23

More Statistics

EPS (TTM) $ -0.22
Beta1.70
Short Percentage of Float3.02%
52-Week Range $0.57 - 2.35
Shares Outstanding (Mil)83.79

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 18 68
EPS ($) -0.29 -0.17 0.10
EPS without NRI ($) -0.29 -0.17 0.10
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CPRX

Headlines

Articles On GuruFocus.com
Catalyst Pharmaceuticals Receives 2017 Beacon Council Award for Contributions in Life Sciences & Hea May 12 2017 
Catalyst Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Upda May 10 2017 
Catalyst Pharmaceuticals Announces Poster Presentation of MuSK-MG clinical data at the 13th Internat May 10 2017 
Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thur May 02 2017 
Catalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored Trial of Firdapse® i Mar 15 2017 
Catalyst Pharmaceuticals to Present at the 29th Annual ROTH Conference Mar 10 2017 
Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference Call and Webcast on Thu Mar 09 2017 
Catalyst Pharmaceuticals Insider Picks Up Shares of Company Oct 05 2015 
Piper Jaffray Remains Bullish on Catalyst Pharmaceuticals Following the Close of its Recent Public O Feb 17 2015 
Weekly CEO Buys Highlight: BH, CLMS, OPK, GPC, CPRX Jan 18 2015 

More From Other Websites
Catalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium May 17 2017
Catalyst Pharmaceuticals Receives 2017 Beacon Council Award for Contributions in Life Sciences &... May 12 2017
Investor Network: Catalyst Pharmaceuticals, Inc. to Host Earnings Call May 11 2017
Catalyst reports 1Q loss May 10 2017
Catalyst Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate... May 10 2017
Catalyst Pharmaceuticals Announces Poster Presentation of MuSK-MG clinical data at the 13th... May 10 2017
What's in Store for Catalyst (CPRX) Stock in Q1 Earnings? May 02 2017
Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on... May 02 2017
Catalyst Pharmaceuticals and ZIOPHARM Oncology Bounce Up On FDA Phase News Mar 28 2017
Financials of Aurinia Pharmaceuticals and Catalyst Pharmaceuticals are Getting Stability Mar 21 2017
Catalyst Pharmaceuticals Inc (CPRX): Here’s What’s Next Mar 16 2017
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results and Provides... Mar 15 2017
Catalyst Pharma Neuromuscular Drug Succeeds In Study Mar 15 2017
Here’s Why Traders Are Piling Into These Five Stocks Mar 15 2017
Catalyst Pharma shares jump 22% premarket on news of positive trial results for rare disease Mar 15 2017
Catalyst Pharma's neuromuscular drug succeeds in study Mar 15 2017
Catalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored Trial of Firdapse® in... Mar 15 2017
Catalyst Pharmaceuticals to Present at the 29th Annual ROTH Conference Mar 10 2017
Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference Call and Webcast on... Mar 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}